We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 16, 2020

Serum AFP Levels and Clinical Outcomes in Patients With Advanced HCC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Serum Alpha-Fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib Versus Placebo in Patients With Advanced Hepatocellular Carcinoma
Clin. Cancer Res 2020 Jul 07;[EPub Ahead of Print], RK Kelley, T Meyer, L Rimassa, P Merle, JW Park, T Yau, SL Chan, JF Blanc, VC Tam, A Tran, V Dadduzio, DW Markby, R Kaldate, AL Cheng, AB El-Khoueiry, GK Abou-Alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading